

**Request Information** 

# FEM1B INHIBITORS

Tech ID: 32345 / UC Case 2021-139-0

# PATENT STATUS

d Application 20240	0287006 08/29/2	2024 2021-139
d Application 43553	327 04/24/2	2024 2021-139
	d Application 4355	d Application 4355327 04/24/2

### **BRIEF DESCRIPTION**

UC Berkeley researchers have discovered novel, specific Fem1b inhibitors. Fem1b is essential in lymphoma and lung cancer cells. Fem1b inhibition could

be beneficial in cancer, metabolic disease, obesity, diabetes and other diseases.

# SUGGESTED USES

» therapeutics

Permalink

# CONTACT

Craig K. Kennedy craig.kennedy@berkeley.edu tel: .



### **INVENTORS**

» Rape, Michael

## OTHER INFORMATION

**CATEGORIZED AS** 

» Medical

» Disease: Cancer

» Disease: Respiratory and

**Pulmonary System** 

**RELATED CASES** 

2021-139-0

### ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

Plasmid Materials

Ubiquitin Materials



University of California, Berkeley Office of Technology Licensing 2150 Shattuck Avenue, Suite 510, Berkeley,CA 94704 Tel: 510.643.7201 | Fax: 510.642.4566 https://ipira.berkeley.edu/ | otl-feedback@lists.berkeley.edu © 2022 - 2024, The Regents of the University of California Terms of use | Privacy Notice